Australian biotech's cortisol blocker fails to improve attention in phase 2 depression study

Actinogen Medical’s cortisol blocker has missed the primary endpoint of a phase 2 study in depression, leaving the Australian biotech to focus on its potential in Alzheimer’s disease.